Loading…
Arrowhead Pharmaceuticals, Inc. is projected to rise to $112.25 by 2027, a +42% move from its current price of $78.99. ARWR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $76.87 | $79.07 | $81.34 | +0.11% |
| May 30 | $76.06 | $79.16 | $82.38 | +0.21% |
| May 31 | $75.46 | $79.24 | $83.21 | +0.32% |
| Jun 1 | $74.98 | $79.33 | $83.93 | +0.43% |
| Jun 2 | $74.56 | $79.41 | $84.58 | +0.54% |
| Jun 3 | $74.19 | $79.50 | $85.18 | +0.64% |
| Jun 4 | $73.86 | $79.58 | $85.75 | +0.75% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $73.86 | $79.58 | $85.75 | +0.75% |
| Week 2 | $72.15 | $80.18 | $89.10 | +1.51% |
| Week 3 | $70.98 | $80.78 | $91.93 | +2.27% |
| Week 4 | $70.10 | $81.39 | $94.49 | +3.03% |
| Week 5 | $69.39 | $82.00 | $96.89 | +3.81% |
| Week 6 | $68.81 | $82.61 | $99.18 | +4.58% |
| Week 7 | $68.32 | $83.23 | $101.40 | +5.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No.
Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc. (ARWR) is a healthcare stock trading at $74.95. It holds a market cap of $10.56B and is ranked 883 by market capitalization. The current price aligns with a forecast path showing an upward price trajectory in the coming years, with the 2026 average price at $74.95 and a bullish signal emerging in later years.
By 2030 the forecast shows an average price of $146.34, and by 2050 an average price of $974.25, with noteworthy upside potential reflected in higher end targets such as $215.17 in 2030, $932.71 in 2040, and $1,828.69 in 2050.
A major floor 30.4% below — a decisive break under it would weaken the trend.
The nearest floor, 13.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.9% away) — a breakout level to watch.
A major ceiling 10.5% above — clearing it would confirm fresh momentum.
Key ARWR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARWR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $77.06 | Buy | $77.38 | Buy |
| MA 10 | $76.67 | Buy | $76.76 | Buy |
| MA 20 | $76.17 | Buy | $75.46 | Buy |
| MA 50 | $69.01 | Buy | $71.20 | Buy |
| MA 100 | $66.72 | Buy | $65.73 | Buy |
| MA 200 | $53.73 | Buy | $55.71 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.76 | Neutral |
| Stoch RSI (14) | 53.25 | Neutral |
| CCI (20) | 87.67 | Neutral |
| Williams %R (14) | -10.00 | Info |
| MACD (12,26,9) | -0.29 | Sell |
| ROC (12) | 8.67 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 90.00 | Sell |
| TRIX (15) | 0.50 | Buy |
| Awesome (5,34) | 3.53 | Buy |
| Ultimate (7,14,28) | 56.19 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 77.69 | Buy |
| ADX (14) | 18.28 | Neutral |
| ATR (14) | 2.04 | Info |
The 30-day technical picture for ARWR carries a bullish sentiment. RSI14 is 50, indicating a neutral short-term momentum around the middle of the range. The 50-day moving average sits at $68.11, with the 200-day moving average at $53.11, implying a constructive trend.
Support is at $63.79 and resistance at $79.69, framing a near-term range that spans roughly from the low $60s to the upper $70s. The stock’s 30-day price range runs from $62.17 to $90.36, and annualized volatility sits near 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $55.01 | $78.99 | $123.67 | 0% | Neutral | |
| $88.74 | $112.25 | $150.60 | +42% | Bullish | |
| $107.09 | $139.32 | $193.89 | +76% | Bullish | |
| $113.94 | $151.78 | $217.45 | +92% | Bullish | |
| $115.97 | $157.75 | $231.61 | +100% | Bullish | |
| $144.46 | $200.30 | $300.46 | +154% | Bullish | |
| $173.85 | $245.40 | $375.28 | +211% | Bullish | |
| $200.31 | $287.53 | $447.48 | +264% | Bullish | |
| $223.30 | $325.70 | $515.10 | +312% | Bullish | |
| $221.18 | $327.60 | $525.91 | +315% | Bullish | |
| $382.10 | $606.81 | $1,037.21 | +668% | Bullish | |
| $618.84 | $1,108.92 | $2,077.02 | +13.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $55.01 | $78.99 | $92.87 | +0.00% |
| June 2026 | $69.31 | $81.45 | $98.04 | +3.12% |
| July 2026 | $73.44 | $87.06 | $106.26 | +6.89% |
| August 2026 | $75.56 | $90.18 | $111.25 | +3.58% |
| September 2026 | $75.38 | $90.48 | $112.59 | +0.33% |
| October 2026 | $77.42 | $93.41 | $117.15 | +3.24% |
| November 2026 | $80.14 | $97.14 | $122.67 | +4.00% |
| December 2026 | $79.92 | $97.30 | $123.67 | +0.16% |
Click any year to see its month-by-month ARWR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ARWR price prediction for 2026 points to an average of $78.99 (low $55.01, high $123.67) — a potential gain of 0% on today's $78.99. A consolidation phase looks the most probable path here.
In 2027, ARWR is projected to trade between $88.74 and $150.60, averaging $112.25 — a potential gain of +42% from today's $78.99. That is up +42% on the projected 2026 average. Momentum favours further upside here.
Arrowhead Pharmaceuticals, Inc.'s 2028 outlook centres on $139.32, within a $107.09 to $193.89 range. That is up +24% on the projected 2027 average. That marks a +76% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ARWR could reach as high as $217.45, with a base case around $151.78 and support toward $113.94 — roughly +92% from $78.99. Momentum favours further upside here.
Expect ARWR to range from $115.97 to $231.61 through 2030. The $157.75 average target implies a +100% move from current prices. That is up +4% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ARWR price prediction for 2031 points to an average of $200.30 (low $144.46, high $300.46) — a potential gain of +154% on today's $78.99. Momentum favours further upside here.
In 2032, ARWR is projected to trade between $173.85 and $375.28, averaging $245.40 — a potential gain of +211% from today's $78.99. That is up +23% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Arrowhead Pharmaceuticals, Inc.'s 2033 outlook centres on $287.53, within a $200.31 to $447.48 range. That is up +17% on the projected 2032 average. That marks a +264% change versus current levels. Momentum favours further upside here.
By 2034, ARWR could reach as high as $515.10, with a base case around $325.70 and support toward $223.30 — roughly +312% from $78.99. Buyers look set to stay in control over this stretch.
Expect ARWR to range from $221.18 to $525.91 through 2035. The $327.60 average target implies a +315% move from current prices. That is up +1% on the projected 2034 average. Momentum favours further upside here.
The ARWR price prediction for 2040 points to an average of $606.81 (low $382.10, high $1,037.21) — a potential gain of +668% on today's $78.99. Buyers look set to stay in control over this stretch.
In 2050, ARWR is projected to trade between $618.84 and $2,077.02, averaging $1,108.92 — a potential gain of +13.0x from today's $78.99. That is up +83% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ARWR today (≈ 12.65983 ARWR) could be worth
$14,038.72
+$13,038.72 (+1304%) by 2050 · US Dollar
Based on the average projected ARWR price of $1,108.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARWRwould be worth at today's price.
$1,000 invested in ARWR on May 27, 2025 (≈ 65.061809 ARWR) would be worth
$5,139.23
+$4,139.23 (+413.9%) today · 5.14× · US Dollar
Based on a ARWR entry price of $15.37 vs. today's $78.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $77.14 | $1,023.98 | +2.4% |
| 1 month ago | $73.6 | $1,073.23 | +7.3% |
| 3 months ago | $63.39 | $1,246.1 | +24.6% |
| 6 months ago | $52.7 | $1,498.86 | +49.9% |
| 1 year ago | $15.37 | $5,139.23 | +413.9% |
| All time (5.0y) ago | $71.91 | $1,098.46 | +9.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARWR forecast.
Our base-case forecast reaches $160.00 around 2031.
Implied market cap at $160.00: $22.54B
The multi-year outlook shows a sustained bullish trajectory, with the 2030 average price at $146.34 and a 95.3% ROI. By 2040 the average rises to $544.65 with a 626.7% ROI, and by 2050 the average reaches $974.25 with a 1199.9% ROI. The forecast also includes higher maximum targets, such as $215.17 in 2030, $932.71 in 2040, and $1,828.69 in 2050, underscoring a wide upside range.
Sentiment is listed as BULLISH for 2030, 2040, and 2050, reflecting an optimistic long-run outlook, though these are estimates and not guarantees and carry inherent uncertainty.
Tap a question to reveal the answer.
These are estimates, not guarantees.
Forecasts show a bullish long-run trajectory with an average price of $146.34 in 2030, rising to $544.65 by 2040 and $974.25 by 2050, with ROIs of 95.3%, 626.7%, and 1199.9% respectively. These are estimates and not guaranteed.
The 2050 forecast lists an average price of $974.25 and a max of $1,828.69, with a 1,199.9% ROI. A move above $1,000 could occur in the max scenario, but these are not guaranteed.
Current price is $74.95 and market cap is $10.56B.
RSI14 is 50. SMA50 is $68.11. SMA200 is $53.11. The 30-day range is $62.17 to $90.36. Support is at $63.79 and resistance at $79.69. Annualized volatility is 50%.
Arrowhead Pharmaceuticals, Inc. Community Discussion
0Share your Arrowhead Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.